

Resource Summary Report

Generated by [RRID](#) on Aug 5, 2026

Molecular Devices: SpectraMax M2 Microplate Reader

RRID:SCR_020307

Type: Tool

Proper Citation

Molecular Devices: SpectraMax M2 Microplate Reader (RRID:SCR_020307)

Resource Information

URL: <https://www.moleculardevices.com/sites/default/files/en/assets/data-sheets/br/spectramax-m2-m2e-microplate-readers.pdf>

Proper Citation: Molecular Devices: SpectraMax M2 Microplate Reader (RRID:SCR_020307)

Description: Multidetector microplate readers with dual monochromators, dual-mode cuvette ports, and top reading capability. Detection modalities include absorbance (UV-Vis Abs) and fluorescence intensity (FI). Endpoint, kinetic, spectrum and area-well scanning read types and the PathCheck Sensor allow homogeneous and heterogeneous microplate assays to be performed in one flexible system. SpectraMax M2 readers provide for easy conversion and optimization of very-low-throughput to medium-high-throughput assays, faster, more precise results and reagent savings. In addition, combined absorbance and fluorescence intensity assays can be run by issuing a single read command.

Resource Type: instrument resource

Keywords: Molecular Devices, Microplate Reader, Instrument Equipment, USEdit

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_020307.pdf

Resource Name: Molecular Devices: SpectraMax M2 Microplate Reader

Resource ID: SCR_020307

Alternate IDs: Model_Number_SpectraMax M2

Record Creation Time: 20220129T080349+0000

Record Last Update: 20260801T190647+0000

Ratings and Alerts

No rating or validation information has been found for Molecular Devices: SpectraMax M2 Microplate Reader.

No alerts have been found for Molecular Devices: SpectraMax M2 Microplate Reader.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Shia CS, et al. (2025) Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody-Drug Conjugate. Molecular cancer therapeutics, 24(12), 1938.